GX Acquisition Corp. (GXGX) to Combine with Celularity in $1.3Bn Deal

GX Acquisition Corp. (NASDAQ:GXGX) announced this morning that it has entered into a definitive merger agreement with clinical stage biotech firm Celularity that would give the combined entity a pro forma enterprise value of $1.29 billion. Celularity has four active and enrolling clinical trials using placental-derived cells to target multiple ailments including several cancer types
Read More